Chevy Chase Trust Holdings LLC Sells 10,226 Shares of Edwards Lifesciences Corporation $EW

Chevy Chase Trust Holdings LLC decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 3.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 304,841 shares of the medical research company’s stock after selling 10,226 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Edwards Lifesciences were worth $23,707,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. True Wealth Design LLC boosted its holdings in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in Edwards Lifesciences during the third quarter valued at approximately $30,000. Finally, Strengthening Families & Communities LLC bought a new position in Edwards Lifesciences during the third quarter valued at approximately $34,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president owned 33,934 shares of the company’s stock, valued at $2,897,284.92. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $85.93, for a total value of $974,446.20. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 61,718 shares of company stock valued at $5,236,281. Company insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on EW. BTIG Research reaffirmed a “buy” rating and issued a $103.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Barclays reissued an “overweight” rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. UBS Group restated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Stock Up 2.2%

EW opened at $83.59 on Tuesday. The firm’s 50 day simple moving average is $82.40 and its two-hundred day simple moving average is $81.60. The company has a market capitalization of $48.55 billion, a PE ratio of 45.68, a PEG ratio of 2.13 and a beta of 0.93. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.